EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Sirolimus for the treatment of steroid-refractory hepatotoxicity following AAV gene therapy in patients with Duchenne muscular dystrophy

Carmen Leon-Astudillo iD, Stephanie M Salabarria iD, Christina B Chadwick iD, Carla D Zingariello iD, Julie Berthy iD, Julia Prascak, Jennifer Shifflet, Gina Killian, Manuela Corti iD, Lawrence Shoemaker iD, Barry J Byrne iD

Journal of Neuromuscular Diseases · 2026-11 · 13 (6) · 1263-1274

DOI: 10.1177/22143602261424971 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Neuromuscular Diseases, online erschienen am 19.03.2026. Verfasst von Carmen Leon-Astudillo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Florida, Gainesville, FL, USA. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Sirolimus, Genetic Therapy, Chemical and Drug Induced Liver Injury. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NICHD NIH HHS, NINDS NIH HHS, Eunice Kennedy Shriver National Institute of Child Health and Human Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adeno-associated virus (AAV)-mediated gene therapy with delandistrogene moxeparvovec-rokl (Elevidys®) is an approved treatment for patients with Duchenne muscular dystrophy (DMD). While generally well tolerated, hepatotoxicity has been observed following its administration, leading to liver failure and death in two reported cases to date.

Methods

This is a case series describing four male patients with DMD, who received delandistrogene moxeparvovec-rokl at a single academic medical center and developed acute liver inflammation. All patients received corticosteroids, with doses increased as abnormalities developed, followed by the addtion of oral sirolimus (goal trough: 3–7 ng/ml), which was used primarily for T-cell immunomodulation. Monitoring included close clinical follow up, serial laboratory testing, and cardiac and functional assessments per institutional protocol.

Results

The patients were between 5 and 16 years of age with a weight between 20.8 and 56.7 kg, (median: 32.5 kg). Three boys were ambulatory. The four patients were receiving chronic corticosteroids for the treatment of DMD prior to delandistrogene moxeparvovec-rokl administration. All cases developed hepatic enzyme elevations five to seven weeks post-gene therapy. Treatment with high-dose corticosteroids led to transient improvement or worsening of laboratory abnormalities, and initiation of adjunctive sirolimus therapy resulted in normalization of gamma-glutamyl transferase and improvement of transaminases within two to four weeks. The duration of sirolimus treatment ranged from four to twelve weeks, during which corticosteroids were successfully weaned. None of the patients experienced hepatic synthetic dysfunction or serious infections.

Conclusions

These cases illustrate a subacute pattern of liver inflammation following AAV-gene therapy and support the potential role of mTOR inhibitors in managing AAV-related hepatotoxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, DuchenneSirolimusGenetic TherapyChemical and Drug Induced Liver InjuryImmunosuppressive AgentsHumansMaleDependovirusChildAdolescentGene Therapy AgentsChild, PreschoolAdrenal Cortex HormonesRecombinant Fusion Proteins

Stichwörter der Autor:innen

AAVDuchenne muscular dystrophygene therapyhepatotoxicityliver injurysirolimus

Substanzen

SirolimusImmunosuppressive Agentsonasemnogene abeparvovecAdrenal Cortex HormonesRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Pediatrics, University of Florida, Gainesville, FL, USA.
  • Powell Gene Therapy Center, University of Florida, Gainesville, FL, USA.
  • Department of Neurology, Montefiore Einstein Medical Center, Bronx, NY, USA.

ORCID-Profile: Carmen Leon-Astudillo, Stephanie M Salabarria, Christina B Chadwick, Carla D Zingariello, Julie Berthy, Manuela Corti, Lawrence Shoemaker, Barry J Byrne

Förderung

  • NICHD NIH HHS
  • NINDS NIH HHS
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Leon-Astudillo, C., Salabarria, S. M., Chadwick, C. B., Zingariello, C. D., Berthy, J., Prascak, J., Shifflet, J., Killian, G., Corti, M., Shoemaker, L., & Byrne, B. J. (2026). Sirolimus for the treatment of steroid-refractory hepatotoxicity following AAV gene therapy in patients with Duchenne muscular dystrophy. Journal of Neuromuscular Diseases, 13(6), 1263-1274. https://doi.org/10.1177/22143602261424971

Vancouver

Leon-Astudillo C, Salabarria SM, Chadwick CB, Zingariello CD, Berthy J, Prascak J, et al. Sirolimus for the treatment of steroid-refractory hepatotoxicity following AAV gene therapy in patients with Duchenne muscular dystrophy. Journal of Neuromuscular Diseases. 2026;13(6):1263-1274. doi:10.1177/22143602261424971

BibTeX
@article{LeonAstudillo2026,
  author = {Leon-Astudillo, Carmen and Salabarria, Stephanie M and Chadwick, Christina B and Zingariello, Carla D and Berthy, Julie and Prascak, Julia and Shifflet, Jennifer and Killian, Gina and Corti, Manuela and Shoemaker, Lawrence and Byrne, Barry J},
  title = {Sirolimus for the treatment of steroid-refractory hepatotoxicity following AAV gene therapy in patients with Duchenne muscular dystrophy},
  journal = {Journal of Neuromuscular Diseases},
  year = {2026},
  volume = {13},
  number = {6},
  pages = {1263--1274},
  doi = {10.1177/22143602261424971}
}
Kostenlos starten →